RT Journal Article
T1 Characterizing Highly Cited Papers in Mass Cytometry through H-Classics
A1 Di Zeo-Sánchez, Daniel Enrique
A1 Sánchez-Núñez, Pablo
A1 Stephens, Camilla
A1 Lucena-González, María Isabel
K1 Bibliometría
AB Mass cytometry (CyTOF) is a relatively novel technique for the multiparametric analysis of single-cell features with an increasing central role in cell biology, immunology, pharmacology, and biomedicine. This technique mixes the fundamentals of flow cytometry with mass spectrometry and is mainly used for in-depth studies of the immune system and diseases with a significant immune load, such as cancer, autoimmune diseases, and viral diseases like HIV or the recently emerged COVID-19, produced by the SARS-CoV-2 coronavirus. The objective of this study was to provide a useful insight into the evolution of the mass cytometry research field, revealing the knowledge structure (conceptual and social) and authors, countries, sources, documents, and organizations that have made the most significant contribution to its development. We retrieved 937 articles from the Web of Science (2010–2019), analysed 71 Highly Cited Papers (HCP) through the H-Classics methodology and computed the data by using Bibliometrix R package. HCP sources corresponded to high-impact journals, such as Nature Biotechnology and Cell, and its production was concentrated in the US, and specifically Stanford University, affiliation of the most relevant authors in the field. HCPs analysis confirmed great interest in the study of the immune system and complex data processing in the mass cytometry research field.
PB IOAP-MPDI
YR 2021
FD 2021-02-02
LK https://hdl.handle.net/10630/26106
UL https://hdl.handle.net/10630/26106
LA eng
NO Di Zeo-Sánchez DE, Sánchez-Núñez P, Stephens C, Lucena MI. Characterizing Highly Cited Papers in Mass Cytometry through H-Classics. Biology. 2021; 10(2):104. https://doi.org/10.3390/biology10020104
NO The present study has been supported by grants of Instituto de Salud Carlos III cofounded by Fondo Europeo de Desarrollo Regional—FEDER (PI19-00883, PT 20/00127)) as well as P18-RT-3364 and “Plan Propio de I+D+I 2020” (IBIMA). CIBERehd and Plataforma ISCiii de Investigación Clínica are funded by Instituto de Salud Carlos III. Partial funding for open access charge: Universidad de Málaga
DS RIUMA. Repositorio Institucional de la Universidad de Málaga
RD 21 ene 2026